Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease
AUTOR(ES)
Young, Jill Melendez
FONTE
American Society of Nephrology
RESUMO
Background and objectives: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2689879Documentos Relacionados
- Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease
- Serum Alkaline Phosphatase and Mortality in African Americans with Chronic Kidney Disease
- The effect of nitric oxide, endothelial nitric oxide synthetase, and asymmetric dimethylarginine in hemorrhoidal disease
- Reduction of functional cardiovascular reserve in the stages of chronic kidney disease
- Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients
